License and supply agreement with Genuine Health
RNS & Investor News
Final Results for the sixteen months to 30 November 2013 and Notice of Annual General Meeting
30 January 2014
These Results are available in PDF format.
To download please click here
I have pleasure in announcing results for the 16 month period from 1 August 2012 to 30 November 2013.
My fellow director, Nicholas Nelson and I were appointed as directors of Ducat Ventures Plc ("Company") following the General Meeting of the Company held on 18 November 2013 at which shareholders approved, inter alia the disposal of the Company's trading activities and a placing which raised proceeds of £285,000 (the "Placing").
Leslie Barber, Alex Dowdeswell and Clive Garston, the former directors of the Company resigned on 18 November 2013.
The Company therefore no longer has any trading activities and is classified as an "Investing Company" pursuant to the AIM Rules. The Company's investing policy is to invest in opportunities within a range of high growth sectors such as natural resources, technology and life sciences.
The board has already identified a number of investment candidates and is performing early stage due diligence. The board is keen to build shareholder value.
The Company also announced today that it has posted a circular to shareholders setting out the terms of an open offer to raise up to £81,352 at a price of 0.004 pence per share. The open offer is being made to shareholders on the register as at 18 November 2013. The rationale for the open offer is to allow the then existing shareholders to invest on terms similar to those in the Placing.
The report and accounts for the period ended 30 November 2013 have been posted to shareholders.
Notice of Annual General Meeting
The Company has posted a Notice of General Meeting to shareholders convening the Annual General Meeting of the Company at 12pm on 24 February 2014 at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN.
30 January 2014
For further information, please contact:
|Ducat Ventures plc||Nicholas Nelson||+44 (0)79 2152 2920|
|Cairn Financial Advisers LLP||Liam Murray / Jo Turner||+44 (0)20 7148 7900|
|Peterhouse Corporate Finance Ltd||Lucy Williams/ Fungai Ndoro||+44 (0)20 7469 0936|
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020